Linked Life Data

11711053

Source:http://linkedlifedata.com/resource/pubmed/id/11711053

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11711053rdf:typepubmed:Citationlld:pubmed
pubmed-article:11711053lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:11711053lifeskim:mentionsumls-concept:C0171023lld:lifeskim
pubmed-article:11711053lifeskim:mentionsumls-concept:C0384853lld:lifeskim
pubmed-article:11711053lifeskim:mentionsumls-concept:C0680242lld:lifeskim
pubmed-article:11711053pubmed:issue2-3lld:pubmed
pubmed-article:11711053pubmed:dateCreated2001-11-16lld:pubmed
pubmed-article:11711053pubmed:abstractTextThe interaction of the psychotropic agent olanzapine with serotonin 5-HT(3) and 5-HT(6) receptors was investigated. Olanzapine did not contract the isolated guinea pig ileum, but blocked contractions induced by the 5-HT(3) receptor agonist 2-methyl serotonin (2-CH(3) 5-HT) with a pK(B) value of 6.38+/-0.03, close to the affinity of the 5-HT(3) receptor antagonist ondansetron. The atypical antipsychotic risperidone (1 microM) did not significantly inhibit 2-CH(3) 5-HT-induced contractions. Olanzapine had high affinity (pK(i)=8.30+/-0.06) for human 5-HT(6) receptors in radioligand binding studies. Olanzapine did not stimulate [35S]guanosine-5'-O-(3-thio)triphosphate ([35S]GTPgammaS) binding to the G protein G(s) in cells containing human 5-HT(6) receptors, but inhibited 5-HT-stimulated [35S]GTPgammaS binding (pK(B)=7.38+/-0.16). Among other antipsychotics investigated, clozapine antagonized 5-HT(6) receptors with a pK(B)=7.42+/-0.15, ziprasidone was three-fold less potent, and risperidone, quetiapine and haloperidol were weak antagonists. Thus, olanzapine was not an agonist, but was a potent antagonist at 5-HT(6) receptors and had marked antagonism at 5-HT(3) receptors.lld:pubmed
pubmed-article:11711053pubmed:languageenglld:pubmed
pubmed-article:11711053pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:citationSubsetIMlld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11711053pubmed:statusMEDLINElld:pubmed
pubmed-article:11711053pubmed:monthNovlld:pubmed
pubmed-article:11711053pubmed:issn0014-2999lld:pubmed
pubmed-article:11711053pubmed:authorpubmed-author:CohenM LMLlld:pubmed
pubmed-article:11711053pubmed:authorpubmed-author:BymasterF PFPlld:pubmed
pubmed-article:11711053pubmed:authorpubmed-author:KennedyJ SJSlld:pubmed
pubmed-article:11711053pubmed:authorpubmed-author:SchenckKKlld:pubmed
pubmed-article:11711053pubmed:authorpubmed-author:DeLappN WNWlld:pubmed
pubmed-article:11711053pubmed:authorpubmed-author:BasievZ GZGlld:pubmed
pubmed-article:11711053pubmed:authorpubmed-author:FalconeJ FJFlld:pubmed
pubmed-article:11711053pubmed:issnTypePrintlld:pubmed
pubmed-article:11711053pubmed:day2lld:pubmed
pubmed-article:11711053pubmed:volume430lld:pubmed
pubmed-article:11711053pubmed:ownerNLMlld:pubmed
pubmed-article:11711053pubmed:authorsCompleteYlld:pubmed
pubmed-article:11711053pubmed:pagination341-9lld:pubmed
pubmed-article:11711053pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:meshHeadingpubmed-meshheading:11711053...lld:pubmed
pubmed-article:11711053pubmed:year2001lld:pubmed
pubmed-article:11711053pubmed:articleTitlePotent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.lld:pubmed
pubmed-article:11711053pubmed:affiliationNeuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285-0501, USA. F.Bymaster@lilly.comlld:pubmed
pubmed-article:11711053pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11711053pubmed:publicationTypeIn Vitrolld:pubmed